Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England.
Nuffield Orthopaedic Centre, Oxford, England.
Syst Rev. 2023 Aug 1;12(1):133. doi: 10.1186/s13643-023-02290-6.
The aim of this systematic review was to summarise the evidence for the clinical effectiveness of revision knee arthroplasty (rKA) compared to non-operative treatment for the management of patients with elective, aseptic causes for a failed knee arthroplasty.
MEDLINE, Embase, AMED and PsychINFO were searched from inception to 1st December 2020 for studies on patients considering elective, aseptic rKA. Patient-relevant outcomes (PROs) were defined as implant survivorship, joint function, quality of life (QoL), complications and hospital admission impact.
No studies compared elective, aseptic rKA to non-operative management. Forty uncontrolled studies reported on PROs following elective, aseptic rKA (434434 rKA). Pooled estimates for implant survivorship were: 95.5% (95% CI 93.2-97.7%) at 1 year [seven studies (5524 rKA)], 90.8% (95% CI 87.6-94.0%) at 5 years [13 studies (5754 rKA)], 87.4% (95% CI 81.7-93.1%) at 10 years [nine studies (2188 rKA)], and 83.2% (95% CI 76.7-89.7%) at 15 years [two studies (452 rKA)]. Twelve studies (2382 rKA) reported joint function and/or QoL: all found large improvements from baseline to follow-up. Mortality rates were low (0.16% to 2% within 1 year) [four studies (353064 rKA)]. Post-operative complications were common (9.1 to 37.2% at 90 days).
Higher-quality evidence is needed to support patients with decision-making in elective, aseptic rKA. This should include studies comparing operative and non-operative management. Implant survivorship following elective, aseptic rKA was ~ 96% at 1 year, ~ 91% at 5 years and ~ 87% at 10 years. Early complications were common after elective, aseptic rKA and the rates summarised here can be shared with patients during informed consent.
PROSPERO CRD42020196922.
本系统评价的目的是总结择期、无菌性膝关节翻修术(rKA)与非手术治疗治疗因膝关节置换失败而选择手术的患者的临床疗效证据。
从 MEDLINE、Embase、AMED 和 PsychINFO 数据库建库至 2020 年 12 月 1 日检索所有考虑择期、无菌性 rKA 的患者相关研究。患者相关结局(PROs)定义为假体生存率、关节功能、生活质量(QoL)、并发症和住院影响。
没有研究比较择期、无菌性 rKA 与非手术治疗。40 项未对照研究报告了择期、无菌性 rKA 后的 PROs(434434 例 rKA)。假体生存率的汇总估计值为:1 年时 95.5%(95%CI 93.2-97.7%)[7 项研究(5524 例 rKA)],5 年时 90.8%(95%CI 87.6-94.0%)[13 项研究(5754 例 rKA)],10 年时 87.4%(95%CI 81.7-93.1%)[9 项研究(2188 例 rKA)],15 年时 83.2%(95%CI 76.7-89.7%)[2 项研究(452 例 rKA)]。12 项研究(2382 例 rKA)报告了关节功能和/或 QoL:所有研究均发现基线到随访时的显著改善。1 年内死亡率较低(0.16%至 2%)[4 项研究(353064 例 rKA)]。术后并发症常见(90 天内 9.1%至 37.2%)。
需要更高质量的证据来支持择期、无菌性 rKA 患者的决策。这应包括比较手术与非手术治疗的研究。择期、无菌性 rKA 后 1 年时假体生存率约为 96%,5 年时约为 91%,10 年时约为 87%。择期、无菌性 rKA 后早期并发症常见,这里总结的发生率可在患者知情同意时告知患者。
PROSPERO CRD42020196922。